Your browser doesn't support javascript.
loading
Development of an inhibitor of the mutagenic SOS response that suppresses the evolution of quinolone antibiotic resistance.
Bradbury, Jacob D; Hodgkinson, Thomas; Thomas, Adam M; Tanwar, Omprakash; La Monica, Gabriele; Rogga, Vanessa V; Mackay, Luke J; Taylor, Emilia K; Gilbert, Kiera; Zhu, Yihua; Sefton, Amber Y; Edwards, Andrew M; Gray-Hammerton, Charlotte J; Smith, Gerald R; Roberts, Paul M; Walsh, Timothy R; Lanyon-Hogg, Thomas.
Afiliação
  • Bradbury JD; Department of Pharmacology, University of Oxford OX1 3QT UK thomas.lanyon-hogg@pharm.ox.ac.uk.
  • Hodgkinson T; Ineos Oxford Institute for Antimicrobial Research, Sir William Dunn School of Pathology, University of Oxford OX1 3RE UK.
  • Thomas AM; Department of Pharmacology, University of Oxford OX1 3QT UK thomas.lanyon-hogg@pharm.ox.ac.uk.
  • Tanwar O; Department of Pharmacology, University of Oxford OX1 3QT UK thomas.lanyon-hogg@pharm.ox.ac.uk.
  • La Monica G; Department of Pharmacology, University of Oxford OX1 3QT UK thomas.lanyon-hogg@pharm.ox.ac.uk.
  • Rogga VV; Department of Pharmacology, University of Oxford OX1 3QT UK thomas.lanyon-hogg@pharm.ox.ac.uk.
  • Mackay LJ; Dipartimento di Scienze e Tecnologie Biologiche, Chimiche e Farmaceutiche (STEBICEF), University of Palermo 90128 Italy.
  • Taylor EK; Department of Pharmacology, University of Oxford OX1 3QT UK thomas.lanyon-hogg@pharm.ox.ac.uk.
  • Gilbert K; Department of Pharmacology, University of Oxford OX1 3QT UK thomas.lanyon-hogg@pharm.ox.ac.uk.
  • Zhu Y; Department of Pharmacology, University of Oxford OX1 3QT UK thomas.lanyon-hogg@pharm.ox.ac.uk.
  • Sefton AY; Department of Pharmacology, University of Oxford OX1 3QT UK thomas.lanyon-hogg@pharm.ox.ac.uk.
  • Edwards AM; Fred Hutchinson Cancer Center Seattle WA 98109-1024 USA.
  • Gray-Hammerton CJ; Department of Infectious Disease, Faculty of Medicine, Imperial College London W2 1NY UK.
  • Smith GR; Department of Infectious Disease, Faculty of Medicine, Imperial College London W2 1NY UK.
  • Roberts PM; Ineos Oxford Institute for Antimicrobial Research, Sir William Dunn School of Pathology, University of Oxford OX1 3RE UK.
  • Walsh TR; Fred Hutchinson Cancer Center Seattle WA 98109-1024 USA.
  • Lanyon-Hogg T; Chemistry Research Laboratory, Department of Chemistry, University of Oxford OX1 3TA UK.
Chem Sci ; 15(25): 9620-9629, 2024 Jun 26.
Article em En | MEDLINE | ID: mdl-38939155
ABSTRACT
Antimicrobial resistance (AMR) is a growing threat to health globally, with the potential to render numerous medical procedures so dangerous as to be impractical. There is therefore an urgent need for new molecules that function through novel mechanisms of action to combat AMR. The bacterial DNA-repair and SOS-response pathways promote survival of pathogens in infection settings and also activate hypermutation and resistance mechanisms, making these pathways attractive targets for new therapeutics. Small molecules, such as IMP-1700, potentiate DNA damage and inhibit the SOS response in methicillin-resistant S. aureus; however, understanding of the structure-activity relationship (SAR) of this series is lacking. We report here the first comprehensive SAR study of the IMP-1700 scaffold, identifying key pharmacophoric groups and delivering the most potent analogue reported to date, OXF-077. Furthermore, we demonstrate that as a potent inhibitor of the mutagenic SOS response, OXF-077 suppresses the rate of ciprofloxacin resistance emergence in S. aureus. This work supports SOS-response inhibitors as a novel means to combat AMR, and delivers OXF-077 as a tool molecule for future development.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article